Return to Today's science sparks archives

2013-07-01

Fig 1b. A positive RET FISH break-apart test. Split green and red signals indicate the presence of a RET fusion.

Fig 1b. A positive RET FISH break-apart test. Split green and red signals indicate the presence of a RET fusion.
  • Drilon A, Wang L, Hasanovic A, Suehara Y, Lipson D, Stephens P, Ross J, Miller V, Ginsberg M, Zakowski MF, Kris MG, Ladanyi M, Rizvi N

  • Cancer Discov. 2013 Jun;3(6):630-5.

2013-07-02

Fig 1. uNGAL by time after PN (dark gray curve), RN (light gray curve) and thoracic surgery (black curve) (PN vs RN p = 005). Dashed curves indicate 95% CI.

Fig 1. uNGAL by time after PN (dark gray curve), RN (light gray curve) and thoracic surgery (black curve) (PN vs RN p = 005). Dashed curves indicate 95% CI.
  • Sprenkle PC, Wren J, Maschino AC, Feifer A, Power N, Ghoneim T, Sternberg I, Fleisher M, Russo P

  • J Urol. 2013 Jul;190(1):159-64.

2013-07-03

Fig 1. a.Overall, disease-specific and recurrence-free survival for mucoepidermoid carcinoma of the major salivary glands. b.Disease-specific survival stratified by presence of facial nerve paralysis. c.Disease-specific survival stratified by histological grade.

Fig 1. a.Overall, disease-specific and recurrence-free survival for mucoepidermoid carcinoma of the major salivary glands. b.Disease-specific survival stratified by presence of facial nerve paralysis. c.Disease-specific survival stratified by histological grade.
  • Ali S, Sarhan M, Palmer FL, Whitcher M, Shah JP, Patel SG, Ganly I

  • Ann Surg Oncol. 2013 Jul;20(7):2396-404.

2013-07-05

Fig 1. Generation and migration of neocortical excitatory and inhibitory neurons.

Fig 1. Generation and migration of neocortical excitatory and inhibitory neurons.
  • Gao P, Sultan KT, Zhang XJ, Shi SH

  • Development. 2013 Jul;140(13):2645-55.

2013-07-08

Fig 1. (a) Unadjusted risk of prostate cancer by fatherhood status. (b) Risk of prostate cancer by fatherhood status, adjusted for socioeconomic status and marital status.

Fig 1. (a) Unadjusted risk of prostate cancer by fatherhood status. (b) Risk of prostate cancer by fatherhood status, adjusted for socioeconomic status and marital status.
  • Wirén SM, Drevin LI, Carlsson SV, Akre O, Holmberg EC, Robinson DE, Garmo HG, Stattin PE

  • Int J Cancer. 2013 Aug 15;133(4):937-43.
Open Access button

2013-07-09

Fig 4. YAP1-TFE3 gene fusion. (A) Schematic representation of the YAP1-TFE3 fusion indicating the loci that are fused together.

Fig 4. YAP1-TFE3 gene fusion. (A) Schematic representation of the YAP1-TFE3 fusion indicating the loci that are fused together.
  • Antonescu CR, Le Loarer F, Mosquera JM, Sboner A, Zhang L, Chen CL, Chen HW, Pathan N, Krausz T, Dickson BC, Weinreb I, Rubin MA, Hameed M, Fletcher CD

  • Genes Chromosomes Cancer. 2013 Aug;52(8):775-84.

2013-07-10

Fig 2. Scatterplot of VO2max (ml/kg/min) by percent total body fat among 115 adult survivors of childhood acute lymphoblastic leukemia and 570 matched NHANES participants. * unadjusted analysis; NHANES, National Health and Nutritional Examination Survey (2003–2004).

Fig 2. Scatterplot of VO2max (ml/kg/min) by percent total body fat among 115 adult survivors of childhood acute lymphoblastic leukemia and 570 matched NHANES participants. * unadjusted analysis; NHANES, National Health and Nutritional Examination Survey (2003–2004).
  • Tonorezos ES, Snell PG, Moskowitz CS, Eshelman-Kent DA, Liu JE, Chou JF, Smith SM, Dunn AL, Church TS, Oeffinger KC

  • Pediatr Blood Cancer. 2013 Aug;60(8):1358-64.

2013-07-11

Fig 1. Disease-specific survival in patients with and without histopathologically confirmed metastatic melanoma in the mesorectal lymph nodes (LNs).

Fig 1. Disease-specific survival in patients with and without histopathologically confirmed metastatic melanoma in the mesorectal lymph nodes (LNs).
  • Perez DR, Trakarnsanga A, Shia J, Nash GM, Temple LK, Paty PB, Guillem JG, Garcia-Aguilar J, Bello D, Ariyan C, Carvajal RD, Weiser MR

  • Ann Surg Oncol. 2013 Jul;20(7):2339-44.

2013-07-12

Fig 3. Flow diagram showing 5-year disease-specific survival (DSS) for cT1T2N0 base of tongue cancer stratified by neck dissection, pathologic N classification, and postoperative radiotherapy (PORT). [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]

Fig 3. Flow diagram showing 5-year disease-specific survival (DSS) for cT1T2N0 base of tongue cancer stratified by neck dissection, pathologic N classification, and postoperative radiotherapy (PORT). [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
  • Iyer NG, Kim L, Nixon IJ, Palmer F, Shah JP, Patel SG, Ganly I

  • Head Neck. 2013 Jul;35(7):999-1006.

2013-07-15

Fig. 1. Correlation of Cp levels and PSA levels. (A) Changes of Cp according to the 2 ATN-224 dose-levels, in study participants.

Fig. 1. Correlation of Cp levels and PSA levels. (A) Changes of Cp according to the 2 ATN-224 dose-levels, in study participants.
  • Lin J, Zahurak M, Beer TM, Ryan CJ, Wilding G, Mathew P, Morris M, Callahan JA, Gordon G, Reich SD, Carducci MA, Antonarakis ES

  • Urol Oncol. 2013 Jul;31(5):581-8.

2013-07-16

Figure 3. Cumulative incidence of day 180 grades III to IV aGVHD by engrafting unit–recipient match at HLA-A,-B,-DRB1 (A) and HLA-A,-B,-C,-DRB1,-DQ (B) alleles.

Figure 3. Cumulative incidence of day 180 grades III to IV aGVHD by engrafting unit–recipient match at HLA-A,-B,-DRB1 (A) and HLA-A,-B,-C,-DRB1,-DQ (B) alleles.
  • Ponce DM, Gonzales A, Lubin M, Castro-Malaspina H, Giralt S, Goldberg JD, Hanash AM, Jakubowski A, Jenq R, Papadopoulos EB, Perales MA, van den Brink MR, Young JW, Boulad F, O'Reilly RJ, Prockop S, Small TN, Scaradavou A, Kernan NA, Stevens CE, Barker JN

  • Biol Blood Marrow Transplant. 2013 Jun;19(6):904-11.

2013-07-17

Fig 1. Cumulative Prevalence of Chronic Health Conditions for Representative Groups of Organ-Specific Outcomes According to Age.

Fig 1. Cumulative Prevalence of Chronic Health Conditions for Representative Groups of Organ-Specific Outcomes According to Age.
  • Hudson MM, Ness KK, Gurney JG, Mulrooney DA, Chemaitilly W, Krull KR, Green DM, Armstrong GT, Nottage KA, Jones KE, Sklar CA, Srivastava DK, Robison LL

  • JAMA. 2013 Jun 12;309(22):2371-81.

2013-07-18

Fig 2. Mean cognitive function score (CFS) by treatment arm over time.

Fig 2. Mean cognitive function score (CFS) by treatment arm over time.
  • Freedman RA, Pitcher B, Keating NL, Ballman KV, Mandelblatt J, Kornblith AB, Kimmick GG, Hurria A, Winer EP, Hudis CA, Cohen HJ, Muss HB; Alliance for Clinical Trials in Oncolog

  • Breast Cancer Res Treat. 2013 Jun;139(2):607-16.

2013-07-19

Fig 1. Grade 3 or greater toxicity: black, chemotherapy plus bevacizumab; stripes, chemotherapy alone.

Fig 1. Grade 3 or greater toxicity: black, chemotherapy plus bevacizumab; stripes, chemotherapy alone.
  • Mohile SG, Hardt M, Tew W, Owusu C, Klepin H, Gross C, Gajra A, Lichtman SM, Feng T, Togawa K, Ramani R, Katheria V, Hansen K, Hurria A; Cancer and Aging Research Group

  • Oncologist. 2013;18(4):408-14.

2013-07-22

Fig 1. Diagram of surgical outcome for patients found to have EHD intraoperatively.

Fig 1. Diagram of surgical outcome for patients found to have EHD intraoperatively.
  • Bickenbach KA, Dematteo RP, Fong Y, Peter Kingham T, Allen PJ, Jarnagin WR, D'Angelica MI

  • Ann Surg Oncol. 2013 Jun;20(6):2029-34.

2013-07-23

Fig 1. Estimates of (A) disease recurrence and (B) cancer-specific mortality incidences according to cigarette smoking status in 864 upper tract urothelial carcinoma patients treated with radical nephroureterectomy. The competing event groups are not displayed in all figures.

Fig 1. Estimates of (A) disease recurrence and (B) cancer-specific mortality incidences according to cigarette smoking status in 864 upper tract urothelial carcinoma patients treated with radical nephroureterectomy. The competing event groups are not displayed in all figures.
  • Rink M, Xylinas E, Margulis V, Cha EK, Ehdaie B, Raman JD, Chun FK, Matsumoto K, Lotan Y, Furberg H, Babjuk M, Pycha A, Wood CG, Karakiewicz PI, Fisch M, Scherr DS, Shariat SF; Upper Tract Urothelial Carcinoma Collaboration

  • Eur Urol. 2013 Jun;63(6):1082-90.

2013-07-24

Fig 1. Trial distribution is shown by clinical disease state. Distribution of 120 trials was analyzed by clinical disease state being explored. Asterisk (*) indicates second-line or beyond).

Fig 1. Trial distribution is shown by clinical disease state. Distribution of 120 trials was analyzed by clinical disease state being explored. Asterisk (*) indicates second-line or beyond).
  • Galsky MD, Hendricks R, Svatek R, Bangs R, Hoffman-Censits J, Clement J, Dreicer R, Guancial E, Hahn N, Lerner SP, O'Donnell PH, Quale DZ, Siefker-Radtke A, Shipley W, Sonpavde G, Vaena D, Vinson J, Rosenberg J

  • Cancer. 2013 Jun 1;119(11):1994-8.

2013-07-25

Fig 1. Characteristics of 302 patients with node-positive (N+) OPSCC who underwent positron emission tomography/computed tomography (PET/CT) within 6–24 weeks following completion of conformal radiotherapy.

Fig 1. Characteristics of 302 patients with node-positive (N+) OPSCC who underwent positron emission tomography/computed tomography (PET/CT) within 6–24 weeks following completion of conformal radiotherapy.
  • Goenka A, Morris LG, Rao SS, Wolden SL, Wong RJ, Kraus DH, Ohri N, Setton J, Lok BH, Riaz N, Mychalczak BR, Schoder H, Ganly I, Shah JP, Pfister DG, Zelefsky MJ, Lee NY

  • Int J Cancer. 2013 Feb 22.

2013-07-26

Fig 2. Kaplan-Meier estimate of overall survival and DFS.

Fig 2. Kaplan-Meier estimate of overall survival and DFS.
  • Ponce DM, Sauter C, Devlin S, Lubin M, Gonzales AM, Kernan NA, Scaradavou A, Giralt S, Goldberg JD, Koehne G, Perales MA, Young JW, Castro-Malaspina H, Jakubowski A, Papadopoulos EB, Barker JN

  • Biol Blood Marrow Transplant. 2013 May;19(5):799-803.

2013-07-29

Fig 1. Nomogram (concordance index = 0.75).

Fig 1. Nomogram (concordance index = 0.75).
  • Nixon IJ, Ganly I, Hann LE, Yu C, Palmer FL, Whitcher MM, Shah JP, Shaha A, Kattan MW, Patel SG

  • Head Neck. 2013 Jul;35(7):1022-5.

2013-07-30

Fig 1. Analysis of T1–2 N1 patients who did not receive radioactive iodine, stratified by thyroglobulin level, size of largest node, and number of nodes excised.

Fig 1. Analysis of T1–2 N1 patients who did not receive radioactive iodine, stratified by thyroglobulin level, size of largest node, and number of nodes excised.
  • Nixon IJ, Ganly I, Patel SG, Palmer FL, Di Lorenzo MM, Grewal RK, Larson SM, Tuttle RM, Shaha A, Shah JP

  • Thyroid. 2013 Jun;23(6):683-94.

2013-07-31

Fig 1. Literature search and selection of studies for analysis flowchart.

Fig 1. Literature search and selection of studies for analysis flowchart.
  • van den Bergh RC, Albertsen PC, Bangma CH, Freedland SJ, Graefen M, Vickers A, van der Poel HG

  • Eur Urol. 2013 Aug;64(2):204-15.

2013-08-01

Fig. 2. Scatter plot with trend line showing the distribution of effective doses for the primary operator plotted against individual procedure time. The trend line demonstrates a tendency to higher doses for longer procedures.

Fig. 2. Scatter plot with trend line showing the distribution of effective doses for the primary operator plotted against individual procedure time. The trend line demonstrates a tendency to higher doses for longer procedures.
  • Ryan ER, Thornton R, Sofocleous CT, Erinjeri JP, Hsu M, Quinn B, Dauer LT, Solomon SB

  • Cardiovasc Intervent Radiol. 2013 Aug;36(4):1063-7.

2013-08-02

Figure 1. Percent of total nephrectomies done as ORN (black curve), LRN (gray curve), OPN (black dashed curve) and LPN (gray dashed curve), excluding 2002 log cases due to small number of cases (84).

Figure 1. Percent of total nephrectomies done as ORN (black curve), LRN (gray curve), OPN (black dashed curve) and LPN (gray dashed curve), excluding 2002 log cases due to small number of cases (84).
  • Poon SA, Silberstein JL, Chen LY, Ehdaie B, Kim PH, Russo P

  • J Urol. 2013 Aug;190(2):464-9.

2013-08-05

Figure 7. Germline Loss of Itgb3 Selectively Impairs Leukemogenesis

Figure 7. Germline Loss of Itgb3 Selectively Impairs Leukemogenesis
  • Miller PG, Al-Shahrour F, Hartwell KA, Chu LP, Järås M, Puram RV, Puissant A, Callahan KP, Ashton J, McConkey ME, Poveromo LP, Cowley GS, Kharas MG, Labelle M, Shterental S, Fujisaki J, Silberstein L, Alexe G, Al-Hajj MA, Shelton CA, Armstrong SA, Root DE, Scadden DT, Hynes RO, Mukherjee S, Stegmaier K, Jordan CT, Ebert BL

  • Cancer Cell. 2013 Jul 8;24(1):45-58.

2013-08-06

Fig 1A Diagram of Glisson’s sheath, and theorized contrast leakage from the arterioles. PV portal vein, A artery, D bile duct, G Glisson’s sheath.

Fig 1A Diagram of Glisson’s sheath, and theorized contrast leakage from the arterioles. PV portal vein, A artery, D bile duct, G Glisson’s sheath.
  • Wang X, Erinjeri JP, Jia X, Gonen M, Brown KT, Sofocleous CT, Getrajdman GI, Brody LA, Thornton RH, Maybody M, Covey AM, Siegelbaum RH, Alago W, Solomon SB

  • Cardiovasc Intervent Radiol. 2013 Aug;36(4):1030-8.

2013-08-07

Fig 1. Ribbon structure of EPO containing a consensus sequence of N- and O-linked carbohydrate domains.

Fig 1. Ribbon structure of EPO containing a consensus sequence of N- and O-linked carbohydrate domains.
  • Wilson RM, Dong S, Wang P, Danishefsky SJ

  • Angew Chem Int Ed Engl. 2013 Jul 22;52(30):7646-65.

2013-08-08

Fig 3. Kaplan–Meier analysis of overall survival in the phase III study MDX010-20.

Fig 3. Kaplan–Meier analysis of overall survival in the phase III study MDX010-20.
  • Wolchok JD, Hodi FS, Weber JS, Allison JP, Urba WJ, Robert C, O'Day SJ, Hoos A, Humphrey R, Berman DM, Lonberg N, Korman AJ

  • Ann N Y Acad Sci. 2013 Jul;1291(1):1-13.

2013-08-09

Fig 1. Prostate-specific antigen (PSA) relapse–free survival curve according to the pre–radiation therapy (RT) biochemical response to neoadjuvant androgen deprivation therapy using a cutpoint of 0.3 ng/mL or less.

Fig 1. Prostate-specific antigen (PSA) relapse–free survival curve according to the pre–radiation therapy (RT) biochemical response to neoadjuvant androgen deprivation therapy using a cutpoint of 0.3 ng/mL or less.
  • Zelefsky MJ, Gomez DR, Polkinghorn WR, Pei X, Kollmeier M

  • Int J Radiat Oncol Biol Phys. 2013 Jul 1;86(3):529-33.

2013-08-12

Fig 1. Overall survival in glioblastoma patients by valproic acid (VA, n=29) or other antiepileptic drug (AED, n=374) use. Median survival was 16.9 or 13.6 months in patients receiving VA or another AED during radiation therapy, respectively (P=.16 by log–rank test). Estimated 2-year and 5-year survival was 34% and 10% or 23% and 5%, respectively.

Fig 1. Overall survival in glioblastoma patients by valproic acid (VA, n=29) or other antiepileptic drug (AED, n=374) use. Median survival was 16.9 or 13.6 months in patients receiving VA or another AED during radiation therapy, respectively (P=.16 by log–rank test). Estimated 2-year and 5-year survival was 34% and 10% or 23% and 5%, respectively.
  • Barker CA, Bishop AJ, Chang M, Beal K, Chan TA

  • Int J Radiat Oncol Biol Phys. 2013 Jul 1;86(3):504-9.

2013-08-13

Fig 1.Knockdown of PAD4 induces EMT in MCF7 cells. (C) IF images of MCF7ctr and shPAD4 cells stained for E-cadherin (green), β-catenin (red), vimentin (red), and nuclei (blue). (Scale bar, 10 μm.)

Fig 1.Knockdown of PAD4 induces EMT in MCF7 cells. (C) IF images of MCF7ctr and shPAD4 cells stained for E-cadherin (green), β-catenin (red), vimentin (red), and nuclei (blue). (Scale bar, 10 μm.)
  • Stadler SC, Vincent CT, Fedorov VD, Patsialou A, Cherrington BD, Wakshlag JJ, Mohanan S, Zee BM, Zhang X, Garcia BA, Condeelis JS, Brown AM, Coonrod SA, Allis CD

  • Proc Natl Acad Sci U S A. 2013 Jul 16;110(29):11851-6.

2013-08-14

Fig 6. USP49 knockdown results in an increase of uH2B level.  (A) Average USP49 (green) and uH2B (control [blue]; USP49 knockdown [red]) occupancy profiles across transcribed regions of expressed genes plus 10 kb upstream of and downstream from the transcriptional start and transcriptional termination sites. (TSS) Transcription start site; (pA) cleavage/polyadenylation site.

Fig 6. USP49 knockdown results in an increase of uH2B level. (A) Average USP49 (green) and uH2B (control [blue]; USP49 knockdown [red]) occupancy profiles across transcribed regions of expressed genes plus 10 kb upstream of and downstream from the transcriptional start and transcriptional termination sites. (TSS) Transcription start site; (pA) cleavage/polyadenylation site.
  • Zhang Z, Jones A, Joo HY, Zhou D, Cao Y, Chen S, Erdjument-Bromage H, Renfrow M, He H, Tempst P, Townes TM, Giles KE, Ma L, Wang H

  • Genes Dev. 2013 Jul 15;27(14):1581-95.

2013-08-15

Fig 6.BCAT1 knockdown affects tumor growth in vivo. (a,b) Cross-sections of tumors 28 d after intracranial injection of U-87MG glioblastoma cells into CD-1 nu/nu mice. H&E staining is shown for mice injected with control nontargeting shRNA–transduced (a) or BCAT1 shRNAI–transduced (b) cells. Scale bars, 1 mm.

Fig 6.BCAT1 knockdown affects tumor growth in vivo. (a,b) Cross-sections of tumors 28 d after intracranial injection of U-87MG glioblastoma cells into CD-1 nu/nu mice. H&E staining is shown for mice injected with control nontargeting shRNA–transduced (a) or BCAT1 shRNAI–transduced (b) cells. Scale bars, 1 mm.
  • Tönjes M, Barbus S, Park YJ, Wang W, Schlotter M, Lindroth AM, Pleier SV, Bai AH, Karra D, Piro RM, Felsberg J, Addington A, Lemke D, Weibrecht I, Hovestadt V, Rolli CG, Campos B, Turcan S, Sturm D, Witt H, Chan TA, Herold-Mende C, Kemkemer R, König R, Schmidt K, Hull WE, Pfister SM, Jugold M, Hutson SM, Plass C, Okun JG, Reifenberger G, Lichter P, Radlwimmer B

  • Nat Med. 2013 Jul;19(7):901-8.

2013-08-16

Fig 4.Structure of vasopressin.

Fig 4.Structure of vasopressin.
  • Wang T, Danishefsky SJ

  • Proc Natl Acad Sci U S A. 2013 Jul 16;110(29):11708-13.

2013-08-19

Fig 14.1. Quantitative analysis of leukocyte recruitment to incisional tail fin wounds. (A) Transmitted-light images of wounded caudal tail fins of zebrafish.

Fig 14.1. Quantitative analysis of leukocyte recruitment to incisional tail fin wounds. (A) Transmitted-light images of wounded caudal tail fins of zebrafish.
  • Enyedi B, Niethammer P

  • Methods Enzymol. 2013;528:237-55.

2013-08-20

Fig 1. Function scores over time for patient with chronic degenerative disease.

Fig 1. Function scores over time for patient with chronic degenerative disease.
  • Vickers AJ, Altman DG

  • BMJ. 2013 Jun 6;346:f3438.

2013-08-21

Figure 2. Time to first pregnancy among survivors and siblings by group (A).

Figure 2. Time to first pregnancy among survivors and siblings by group (A).
  • Barton SE, Najita JS, Ginsburg ES, Leisenring WM, Stovall M, Weathers RE, Sklar CA, Robison LL, Diller L

  • Lancet Oncol. 2013 Aug;14(9):873-81.

2013-08-22

Figure 3. Pretreatment tumour sample with over-expression of phospho-S6 and phospho-4E-BP1 and an absence of phosphatase and tensin homologue (PTEN) staining in tumour cells.

Figure 3. Pretreatment tumour sample with over-expression of phospho-S6 and phospho-4E-BP1 and an absence of phosphatase and tensin homologue (PTEN) staining in tumour cells.
  • Milowsky MI, Iyer G, Regazzi AM, Al-Ahmadie H, Gerst SR, Ostrovnaya I, Gellert LL, Kaplan R, Garcia-Grossman IR, Pendse D, Balar AV, Flaherty AM, Trout A, Solit DB, Bajorin DF

  • BJU Int. 2013 Aug;112(4):462-70.

2013-08-23

Figure 1. Tumor of transition zone origin on tissue microarray core – H&E (A) and corresponding positive ERG immunohistochemistry (B); FISH (C).

Figure 1. Tumor of transition zone origin on tissue microarray core – H&E (A) and corresponding positive ERG immunohistochemistry (B); FISH (C).
  • Gopalan A, Leversha MA, Dudas ME, Maschino AC, Chang J, Al-Ahmadie HA, Chen YB, Tickoo SK, Reuter VE, Fine SW

  • Histopathology. 2013 Aug;63(2):279-86.

2013-08-26

Fig 1. Study informatics system events tracking. This represents a schematic of the study's data entry, processing, and transfer events.

Fig 1. Study informatics system events tracking. This represents a schematic of the study's data entry, processing, and transfer events.
  • Pietanza MC, Basch EM, Lash A, Schwartz LH, Ginsberg MS, Zhao B, Shouery M, Shaw M, Rogak LJ, Wilson M, Gabow A, Latif M, Lin KH, Wu Q, Kass SL, Miller CP, Tyson L, Sumner DK, Berkowitz-Hergianto A, Sima CS, Kris MG

  • J Clin Oncol. 2013 Jun 1;31(16):2004-9.

2013-08-27

Fig 4. Host OPN selectively enriches stem-like cancer cells in B16F10 cells.

Fig 4. Host OPN selectively enriches stem-like cancer cells in B16F10 cells.
  • Kumar S, Sharma P, Kumar D, Chakraborty G, Gorain M, Kundu GC

  • PLoS One. 2013 Jul 23;8(7):e69116.
Open Access button

2013-08-28

Fig 5. Autoradiography, histology, and fluorescence microscopy of resected SW1222 xenografts from multimodality pretargeting experiment.

Fig 5. Autoradiography, histology, and fluorescence microscopy of resected SW1222 xenografts from multimodality pretargeting experiment.
  • Zeglis BM, Sevak KK, Reiner T, Mohindra P, Carlin SD, Zanzonico P, Weissleder R, Lewis JS

  • J Nucl Med. 2013 Aug;54(8):1389-96.

2013-08-29

Figure 1. Immunohistochemical staining for ALK. Specimens (A–C) show negative ALK immunohistochemical staining for 3 patients with KRAS mutations and abnormal ALK FISH. Specimens (D–F) depict positive ALK immunohistochemical staining from 3 representative patients with positive ALK FISH.

Figure 1. Immunohistochemical staining for ALK. Specimens (A–C) show negative ALK immunohistochemical staining for 3 patients with KRAS mutations and abnormal ALK FISH. Specimens (D–F) depict positive ALK immunohistochemical staining from 3 representative patients with positive ALK FISH.
  • Gainor JF, Varghese AM, Ou SH, Kabraji S, Awad MM, Katayama R, Pawlak A, Mino-Kenudson M, Yeap BY, Riely GJ, Iafrate AJ, Arcila ME, Ladanyi M, Engelman JA, Dias-Santagata D, Shaw AT

  • Clin Cancer Res. 2013 Aug 1;19(15):4273-81.

2013-08-30

Figure 1. PLZF-TG T cells display effector–memory phenotype with innate-like features. T cells from B6-WT or PLZF-TG splenocytes were counted and analyzed by flow cytometry. Extracellular staining of live CD4+ and CD8+ events showing representative plots (A) and pooled data (n = 4; B) are depicted.

Figure 1. PLZF-TG T cells display effector–memory phenotype with innate-like features. T cells from B6-WT or PLZF-TG splenocytes were counted and analyzed by flow cytometry. Extracellular staining of live CD4+ and CD8+ events showing representative plots (A) and pooled data (n = 4; B) are depicted.
  • Ghosh A, Holland AM, Dogan Y, Yim NL, Rao UK, Young LF, West ML, Singer NV, Lee H, Na IK, Tsai JJ, Jenq RR, Penack O, Hanash AM, Lezcano C, Murphy GF, Liu C, Sadelain M, Sauer MG, Sant'angelo D, van den Brink MR

  • Cancer Res. 2013 Aug 1;73(15):4687-4696.

2013-09-03

Fig 1. Sample isodose curves of DP-IMRT and IMRT plus AP/PA whole lung irradiation plans for a representative 12-year-old patient with ESFT of the upper rib.

Fig 1. Sample isodose curves of DP-IMRT and IMRT plus AP/PA whole lung irradiation plans for a representative 12-year-old patient with ESFT of the upper rib.
  • Yang JC, Wexler LH, Meyers PA, Happersett L, La Quaglia MP, Wolden SL

  • Pediatr Blood Cancer. 2013 Oct;60(10):1616-20.

2013-09-04

Fig 1. County mammography capacity and total mammography machines in the United States are shown for 2000 through 2010.

Fig 1. County mammography capacity and total mammography machines in the United States are shown for 2000 through 2010.
  • Elkin EB, Atoria CL, Leoce N, Bach PB, Schrag D

  • Cancer. 2013 Aug 13.

2013-09-05

Figure 2. PET/CT images of 18F-FDG and 124I-IAZGP in a head and neck cancer patient. Cross-sectional fused PET/CT images comparing 18 F-FDG (E and F left, G top) with 124I-IAZGP at 6 h (E and F right, G bottom).

Figure 2. PET/CT images of 18F-FDG and 124I-IAZGP in a head and neck cancer patient. Cross-sectional fused PET/CT images comparing 18 F-FDG (E and F left, G top) with 124I-IAZGP at 6 h (E and F right, G bottom).
  • O'Donoghue JA, Guillem JG, Schöder H, Lee NY, Divgi CR, Ruby JA, Humm JL, Lee-Kong SA, Burnazi EM, Cai S, Carlin SD, Leibold T, Zanzonico PB, Ling CC

  • EJNMMI Res. 2013 Jun 3;3(1):42.

2013-09-06

Fig 4. Computed tomography scans at (A) baseline and (B) after 13 months of treatment with PD0332991.

Fig 4. Computed tomography scans at (A) baseline and (B) after 13 months of treatment with PD0332991.
  • Dickson MA, Tap WD, Keohan ML, D'Angelo SP, Gounder MM, Antonescu CR, Landa J, Qin LX, Rathbone DD, Condy MM, Ustoyev Y, Crago AM, Singer S, Schwartz GK

  • J Clin Oncol. 2013 Jun 1;31(16):2024-8.

2013-09-09

Figure 4ab. Somatic Defects in piwi Mutant Larval Gonads Are Associated with Defective Escort Cell Morphology.

Figure 4ab. Somatic Defects in piwi Mutant Larval Gonads Are Associated with Defective Escort Cell Morphology.
  • Jin Z, Flynt AS, Lai EC

  • Curr Biol. 2013 Aug 5;23(15):1442-8.

2013-09-10

Fig 2. Kaplan–Meier survival analysis of overall survival using landmark analysis. The time origin is shifted 7 months to exclude those patients in the nonconversion group that died or were lost to follow-up before the earliest resection was performed.

Fig 2. Kaplan–Meier survival analysis of overall survival using landmark analysis. The time origin is shifted 7 months to exclude those patients in the nonconversion group that died or were lost to follow-up before the earliest resection was performed.
  • Ammori JB, Kemeny NE, Fong Y, Cercek A, Dematteo RP, Allen PJ, Kingham TP, Gonen M, Paty PB, Jarnagin WR, D'Angelica MI

  • Ann Surg Oncol. 2013 Sep;20(9):2901-7.

2013-09-11

Fig 1. Desmoplastic melanoma (combined cellular spindle cell and desmoplastic melanoma). A) Hematoxylin and eosin-stain of the tumor. B) The tumor cells are homogeneously positive for S100 protein. C) The vast majority of tumor cells are negative for p16.

Fig 1. Desmoplastic melanoma (combined cellular spindle cell and desmoplastic melanoma). A) Hematoxylin and eosin-stain of the tumor. B) The tumor cells are homogeneously positive for S100 protein. C) The vast majority of tumor cells are negative for p16.
  • Blokhin E, Pulitzer M, Busam KJ

  • J Cutan Pathol. 2013 Sep;40(9):796-800.

2013-09-12

Fig 1. Distribution and density of total PSA at baseline among cases and controls.

Fig 1. Distribution and density of total PSA at baseline among cases and controls.
  • Larsen SB, Brasso K, Iversen P, Christensen J, Christiansen M, Carlsson S, Lilja H, Friis S, Tjønneland A, Dalton SO

  • Eur J Cancer. 2013 Sep;49(14):3041-8.

2013-09-13

Fig 2. Histopathologic findings of granulomatous mycosis fungoides cases. Superficial and deep infiltrate with perivascular granuloma formation, atypical lymphocytes, multinucleated giant cells, and scattered eosinophils. (C); dense and diffuse lymphohistiocytic infiltrate with multinucleated giant cells and epidermotropism.

Fig 2. Histopathologic findings of granulomatous mycosis fungoides cases. Superficial and deep infiltrate with perivascular granuloma formation, atypical lymphocytes, multinucleated giant cells, and scattered eosinophils. (C); dense and diffuse lymphohistiocytic infiltrate with multinucleated giant cells and epidermotropism.
  • Li JY, Pulitzer MP, Myskowski PL, Dusza SW, Horwitz S, Moskowitz A, Querfeld C

  • J Am Acad Dermatol. 2013 Sep;69(3):366-374.e4.

2013-09-16

Fig 2. Study flow diagram. Short-segment BE defined as ≤3 cm. ∗Early cancer includes HGD and ImCa. †Endoscopic images were not available for review.

Fig 2. Study flow diagram. Short-segment BE defined as ≤3 cm. ∗Early cancer includes HGD and ImCa. †Endoscopic images were not available for review.
  • Enestvedt BK, Lugo R, Guarner-Argente C, Shah P, Falk GW, Furth E, Ginsberg GG

  • Gastrointest Endosc. 2013 Sep;78(3):462-7.

2013-09-17

Fig 2  Methods to quantify cell-in-cell formation by entosis. (a) Cytospin method.(b) Time-lapse in soft agar method.

Fig 2 Methods to quantify cell-in-cell formation by entosis. (a) Cytospin method.(b) Time-lapse in soft agar method.
  • Sun Q, Overholtzer M

  • Methods Mol Biol. 2013;1004:59-66.

2013-09-18

Fig 1. CancerLinQ process model. The learning health care system in oncology can be represented schematically as two interlocking circles.

Fig 1. CancerLinQ process model. The learning health care system in oncology can be represented schematically as two interlocking circles.
  • Sledge GW, Hudis CA, Swain SM, Yu PM, Mann JT, Hauser RS, Lichter AS

  • J Oncol Pract. 2013 May;9(3):145-8.

2013-09-19

Fig 1. Characterization of the anti-DENV efficacy of MTX and FUDR. (A) HEK293 cells were treated with DMSO only, 10 μM MTX, or 10 μM FUDR and infected with DENV2 at an MOI of 0.5 PFU/cell. Cells were analyzed 48 h p.i. by immunofluorescence for the presence of DENV-Env protein.

Fig 1. Characterization of the anti-DENV efficacy of MTX and FUDR. (A) HEK293 cells were treated with DMSO only, 10 μM MTX, or 10 μM FUDR and infected with DENV2 at an MOI of 0.5 PFU/cell. Cells were analyzed 48 h p.i. by immunofluorescence for the presence of DENV-Env protein.
  • Fischer MA, Smith JL, Shum D, Stein DA, Parkins C, Bhinder B, Radu C, Hirsch AJ, Djaballah H, Nelson JA, Früh K

  • J Virol. 2013 Sep;87(17):9411-9.

2013-09-20

Fig 1. MIR143-NOTCH2 gene fusion in a malignant gastrointestinal glomus tumor (GT1). C,D: FISH studies confirming break-apart signals in both NOTCH2 and MIR143 (Red, centromeric; Green, telomeric).

Fig 1. MIR143-NOTCH2 gene fusion in a malignant gastrointestinal glomus tumor (GT1). C,D: FISH studies confirming break-apart signals in both NOTCH2 and MIR143 (Red, centromeric; Green, telomeric).
  • Mosquera JM, Sboner A, Zhang L, Chen CL, Sung YS, Chen HW, Agaram NP, Briskin D, Basha BM, Singer S, Rubin MA, Tuschl T, Antonescu CR

  • Genes Chromosomes Cancer. 2013 Nov;52(11):1075-87.

2013-09-23

Figure 2: The relationship of biomarker prevalence versus expected treatment. This hypothetical graph demonstrates the continuous relationship between the biomarker and the expected benefit of the drug, normalized to risk.

Figure 2: The relationship of biomarker prevalence versus expected treatment. This hypothetical graph demonstrates the continuous relationship between the biomarker and the expected benefit of the drug, normalized to risk.
  • Fridlyand J, Simon RM, Walrath JC, Roach N, Buller R, Schenkein DP, Flaherty KT, Allen JD, Sigal EV, Scher HI

  • Nat Rev Drug Discov. 2013 Sep 6.

2013-09-24

Fig 3. Whole-mount views of the entire pineal resection specimen as seen in hematoxylin-eosin (H-E) stained material (a) and immunohistochemical preparation for MIB-1/Ki-67.

Fig 3. Whole-mount views of the entire pineal resection specimen as seen in hematoxylin-eosin (H-E) stained material (a) and immunohistochemical preparation for MIB-1/Ki-67.
  • Bonci GA, Rosenblum MK, Gilheeney SW, Dunkel IJ, Holodny AI

  • Pediatr Radiol. 2013 Sep;43(9):1231-4.

2013-09-25

Fig 1. Mechanism of CAD Effect on LMPLeft: tumor cell lysosomes contain lower SM levels than normal cell lysosomes and a compensatory lower ASM activity.Right: CADs functionally inhibit ASM by physico-chemical mechanisms.

Fig 1. Mechanism of CAD Effect on LMPLeft: tumor cell lysosomes contain lower SM levels than normal cell lysosomes and a compensatory lower ASM activity.Right: CADs functionally inhibit ASM by physico-chemical mechanisms.
  • Gulbins E, Kolesnick RN

  • Cancer Cell. 2013 Sep 9;24(3):279-81.

2013-09-26

Fig. 1. Schematic structures of KIT and PDGFR.

Fig. 1. Schematic structures of KIT and PDGFR.
  • Balachandran VP, Dematteo RP

  • Surg Oncol Clin N Am. 2013 Oct;22(4):805-21.

2013-09-27

Fig. 2. Binding of estrogen to the intracellular ER leads to proliferation and cell survival.

Fig. 2. Binding of estrogen to the intracellular ER leads to proliferation and cell survival.
  • Cadoo KA, Traina TA, King TA

  • Surg Oncol Clin N Am. 2013 Oct;22(4):823-40.

2013-09-30

Fig. 1. Stereotactic body radiotherapy (SBRT) and high-dose-rate (HDR) axial color wash dosimetry for normal tissue–prioritized plan. Color wash of the SBRT normal tissue–prioritized plan (left) and the corresponding patient's HDR plan (right). The axis is percent of the prescribed dose.

Fig. 1. Stereotactic body radiotherapy (SBRT) and high-dose-rate (HDR) axial color wash dosimetry for normal tissue–prioritized plan. Color wash of the SBRT normal tissue–prioritized plan (left) and the corresponding patient's HDR plan (right). The axis is percent of the prescribed dose.
  • Spratt DE, Scala LM, Folkert M, Voros L, Cohen GN, Happersett L, Katsoulakis E, Zelefsky MJ, Kollmeier MA, Yamada Y

  • Brachytherapy. 2013 Sep-Oct;12(5):428-33.

2013-10-01

Fig 4. Effect of TLR2 activation in in vitro-cultured primary normal BM CD34+ cells. (a) Flow cytometry analysis of normal CD34+ cells after being treated with MALP2 or PAM3CSK4 for 48 h. Compared with control, treatment resulted in a decreased percentage of early erythroid progenitor cells marked with CD71+ and HLA-DR.

Fig 4. Effect of TLR2 activation in in vitro-cultured primary normal BM CD34+ cells. (a) Flow cytometry analysis of normal CD34+ cells after being treated with MALP2 or PAM3CSK4 for 48 h. Compared with control, treatment resulted in a decreased percentage of early erythroid progenitor cells marked with CD71+ and HLA-DR.
  • Wei Y, Dimicoli S, Bueso-Ramos C, Chen R, Yang H, Neuberg D, Pierce S, Jia Y, Zheng H, Wang H, Wang X, Nguyen M, Wang SA, Ebert B, Bejar R, Levine R, Abdel-Wahab O, Kleppe M, Ganan-Gomez I, Kantarjian H, Garcia-Manero G

  • Leukemia. 2013 Sep;27(9):1832-40.